CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 348 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00724958
NCT00724958N/ACompleted
CompareCT.gov

Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension

Merck Sharp & Dohme LLC·observational·Posted Jul 30, 2008·Updated Oct 2, 2015

In Brief

An observational study evaluating Infliximab for Crohn's Disease. Completed, enrolled 348 participants.

Detailed Summary

The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
CollaboratorsCentocor, Inc.

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartDec 1, 2004
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 17.9 years ago

Interventions

Infliximabbiological

Not specified in the protocol.